




**ALKEM**

**ALKEM LABORATORIES LTD.**

Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg,  
Lower Parel, Mumbai - 400 013. Phone : 022-3982 9999, Fax : 022-2495 2955  
Email : contact@alkem.com Website : www.alkemlabs.com  
CIN :- L00305MH1973PLC174201



28<sup>th</sup> March, 2018

<b>The Corporate Relationship Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	---

Dear Sirs

**Sub: US FDA Inspection at Alkem's manufacturing facilities located at Amaliya, Daman, India and St. Louis, USA.**

This is to inform you that the US FDA had conducted an inspection at the Company's manufacturing facility located at Amaliya, Daman, India from 19<sup>th</sup> March, 2018 to 27<sup>th</sup> March, 2018.

Post the inspection, the Company has received a Form 483 with thirteen observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA observations and the same is proposed to be filed within the timeline stipulated by the US FDA.

Further to this, please also be informed that the US FDA had conducted an inspection at the Company's manufacturing facility located at St. Louis, USA from 12<sup>th</sup> March, 2018 to 16<sup>th</sup> March, 2018. In response to the one Form 483 observation issued by the US FDA, the Company has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.

Kindly take note of the same.

Sincerely,  
For Alkem Laboratories Limited

  
**Manish Narang**  
**President - Legal, Company Secretary & Compliance Officer**